Results 71 to 80 of about 1,956,144 (286)

A systematic review of the mechanism of action and potential medicinal value of codonopsis pilosula in diseases

Frontiers in Pharmacology
As a traditional Chinese medicinal herb with a long history, Codonopsis pilosula (CP) has attracted much attention from the medical community in recent years. This review summarizes the research progress of CP in the medical field in the past 5 years. By
Huina Guo, Huina Guo, YiChen Lou, YiChen Lou, YiChen Lou, Xiaofang Hou, Xiaofang Hou, Xiaofang Hou, Qi Han, Qi Han, Yujia Guo, Yujia Guo, Zhongxun Li, Zhongxun Li, Xiaoya Guan, Xiaoya Guan, Hongliang Liu, Hongliang Liu, Hongliang Liu, Hongliang Liu, Chunming Zhang, Chunming Zhang, Chunming Zhang   +22 more
doaj   +1 more source

Optimizing combination therapies with existing and future CML drugs. [PDF]

PLoS ONE, 2010
Small-molecule inhibitors imatinib, dasatinib and nilotinib have been developed to treat Chromic Myeloid Leukemia (CML). The existence of a triple-cross-resistant mutation, T315I, has been a challenging problem, which can be overcome by finding new ...
Allen A Katouli, Natalia L Komarova
doaj   +1 more source

Epigenetic polypharmacology: from combination therapy to multitargeted drugs [PDF]

, 2016
The modern drug discovery process has largely focused its attention in the so-called magic bullets, single chemical entities that exhibit high selectivity and potency for a particular target.
A Anighoro, A Dey, A Ganesan, A Mai, A Nudelman, AF Fliri, B Al-Lazikani, B Knoechel, B Meunier, BC Smith, BC Smith, BC Smith, BE Gryder, C Choudhary, C Corminboeuf, C Liu, C Qian, C Tang, C Yu, C Zwergel, C-W Chen, CM Fillmore, CM Grozinger, CY Fong, D Bixby, D Gallenkamp, D Matei, D Passarella, D Rotili, D Sharma, DA Mele, E Bicaku, E Borretto, E Nicodeme, F Sun, F-W Peng, G Zhang, G-L Chen, GE Winter, GL Verdine, H Patel, HS Bandukwala, HS Takhar, J Fischer, J Lu, J Schneider, J Zhao, J Zuber, J-B Chen, J-F Couture, J-PJ Issa, JC Culhane, JL Avalos, JM Burg, JS Kirk, K Agger, K Chen, K K-p, K Pruitt, K Zhao, KB Daniel, KT Thurn, L Chen, L Chen, LK Gediya, M Buchwald, M De los Santos, M Yang, M Zuo, MA Dawson, MA Dawson, MA Park, MB Poulin, MC Chen, MJ Keiser, MM Singh, MS Finnin, N Geva-Zatorsky, OW Rokhlin, P Anand, P Bamborough, P Filippakopoulos, P Hu, P Hu, P Jones, P Rathert, PA Marks, PK Mazur, PN Munster, Q Wang, R Anand, R Morphy, R Morphy, R Nimmanapalli, R Pereira, R Pili, R Álvarez, RA Copeland, RA Juergens, RL Momparler, S Daujat, S Klimasauskas, S Mahboobi, S Mahboobi, S Zhao, SC Hodawadekar, SJ Atkinson, SS Ng, T Beckers, T Finkel, T Kokkola, T Qiu, T Vaissiere, T-G Lee, TH Luu, TJ Galloway, TM Pitts, W Guerrant, WF Hawse, X Cai, X Cheng, X Sun, X Zhang, Y Ling, Y Zhang, Z Chen   +125 more
core   +1 more source

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman, Katherine K. Matthay, Fabienne Hollinger, Catriona Black, Ann A. Lazar, Miguel Pampaloni, Steven G. DuBois, Kieuhoa T. Vo   +7 more
wiley   +1 more source

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells [PDF]

, 2016
Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation
Bown, James, Deeni, Yusuf Y., Goltsov, Alexey, Harrison, David J., Khalil, Hilal S., Langdon, Simon P., Soininen, Tero   +6 more
core   +3 more sources

Efficacy and Safety Analysis of Roxarestat in Regulating Renal Anemia in Patients on Maintenance Hemodialysis

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley   +1 more source

Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences [PDF]

, 2015
Herbal medicines are currently in high demand, and their popularity is steadily increasing. Because of their perceived effectiveness, fewer side effects and relatively low cost, they are being used for the management of numerous medical conditions ...
Horie, Toshiharu, Oga, Enoche Florence, Sekine, Shuichi, Shitara, Yoshihisa   +3 more
core   +1 more source

Therapeutic Apheresis for Intravenous Methylprednisolone‐Refractory Neuromyelitis Optica Spectrum Disorder: Clinical and Radiological Outcomes in a Single‐Center Case Series

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system. High‐dose intravenous methylprednisolone (IVMP) is the standard first‐line therapy for acute attacks, although some patients remain refractory.
Wataru Horiguchi, Daisuke Katagiri, Takeyuki Watadani, Shunichi Matsuda, Hiroshi Kaneko, Noritoshi Arai   +5 more
wiley   +1 more source

Single and combined strategies for mesenchymal stem cell exosomes alleviate liver fibrosis: a systematic review and meta-analysis of preclinical animal models

Frontiers in Pharmacology
Background: The efficacy of mesenchymal stem cells (MSCs) in treating liver fibrosis has been supported by various clinical studies. However, stem cell transplantation is limited in clinical application due to its low survival rate, low liver ...
Xiaolei Zhou, Xiaolei Zhou, Yan Xu, Yan Xu, Xuesong Wang, Xuesong Wang, Wenming Lu, Wenming Lu, Xingkun Tang, Xingkun Tang, Yu Jin, Junsong Ye, Junsong Ye, Junsong Ye, Junsong Ye, Junsong Ye   +15 more
doaj   +1 more source

Combination antiretroviral drugs in PLGA nanoparticle for HIV-1

BMC Infectious Diseases, 2009
Background Combination antiretroviral (AR) therapy continues to be the mainstay for HIV treatment. However, antiretroviral drug nonadherence can lead to the development of resistance and treatment failure. We have designed nanoparticles (NP) that contain
Sharma Akhilesh, Shibata Annemarie, Christensen Keith, Belgum Todd, Destache Christopher J, Dash Alekha   +5 more
doaj   +1 more source